Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Caspases
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Caspases

[0246-99] FAM-FLICA® Caspase 8 Assay Test - 25T
FAM-FLICA® Caspase 8 Assay Test - 25T
500.00 € 500.0 EUR
[0246-910] FAM-FLICA® Caspase 8 Assay Test - 100 Tests
FAM-FLICA® Caspase 8 Assay Test - 100 Tests
890.00 € 890.0 EUR
[0246-93] FAM-FLICA® Caspase 3 & 7 Assay Test - 25T
FAM-FLICA® Caspase 3 & 7 Assay Test - 25T
500.00 € 500.0 EUR
[0246-97] FAM-FLICA® Caspase 1 YVAD Assay Test - 25T
FAM-FLICA® Caspase 1 YVAD Assay Test - 25T
438.00 € 438.0 EUR
[0246-98] FAM-FLICA® Caspase 1 YVAD Assay Test - 100 assays
FAM-FLICA® Caspase 1 YVAD Assay Test - 100 assays
882.00 € 882.0 EUR
[0355-40502-50ul] Cleaved-Caspase-8 (D384) Polyclonal Antibody - 50ul
Cleaved-Caspase-8 (D384) Polyclonal Antibody - 50ul
510.00 € 510.0 EUR
[0796-BF0711] Cleaved-Caspase 3 (Asp175), p17 Antibody - 50 µL
Cleaved-Caspase 3 (Asp175), p17 Antibody - 50 µL
375.00 € 375.0 EUR
[544-MBS458138-96T] Mouse Caspase 9 ELISA, 96 test
Mouse Caspase 9 ELISA, 96 test
835.00 € 835.0 EUR
[0544-MBS450868-96T] Mouse Caspase 3 ELISA, 96 test
Mouse Caspase 3 ELISA, 96 test
802.00 € 802.0 EUR
[0812-SL0417Hu-96T] Human Caspase 12(CASP12)ELISA Test, 96 T
Human Caspase 12(CASP12)ELISA Test, 96 T
499.00 € 499.0 EUR
[0544-MBS9425893-96] Rat Caspase-3 ELISA Test, 96T
Rat Caspase-3 ELISA Test, 96T
685.00 € 685.0 EUR
[0037-10403] NucView® Caspase-3 Enzyme Substrates - 100 uL (1 mM in PBS), NucView® 488
NucView® Caspase-3 Enzyme Substrates - 100 uL (1 mM in PBS), NucView® 488
550.00 € 550.0 EUR
[0037-10405] NucView® Caspase-3 Enzyme Substrates - 100 uL (1 mM in DMSO), NucView® 405
NucView® Caspase-3 Enzyme Substrates - 100 uL (1 mM in DMSO), NucView® 405
588.00 € 588.0 EUR
[0037-30029-T] NucView® 488 Caspase-3 Assay Test for Live Cells - Trial size (25 assays)
NucView® 488 Caspase-3 Assay Test for Live Cells - Trial size (25 assays)
255.00 € 255.0 EUR
[0710-FNab01284-100ug.] anti- Caspase 1 antibody, 100 ug.
anti- Caspase 1 antibody, 100 ug.
375.00 € 375.0 EUR
[0607-A1920-5mG.] Z-DEVD-FMK - Caspase-3 inhibitor 5mG.
Z-DEVD-FMK - Caspase-3 inhibitor 5mG.
330.00 € 330.0 EUR
[0607-A1920-1mG.] Z-DEVD-FMK - Caspase-3 inhibitor 1mG.
Z-DEVD-FMK - Caspase-3 inhibitor 1mG.
282.00 € 282.0 EUR
  • 1
  • 2

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)